XBiotech Inc. (XBIT) Stock Score, Valuation & Financial Research

XBiotech Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for XBIT

XBiotech Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.16. These figures are a research snapshot, not a buy or sell recommendation.

What XBiotech Inc. does

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

XBiotech is a clinical-stage biopharmaceutical company focused on the discovery and development of True Human™ antibody therapeutics. The company's business model involves the research and development of drug candidates for potential sale or licensing prior to receiving marketing authorization, and it does not currently generate revenue from product sales.

Products and services

  • The company develops True Human™ antibody therapies derived from individuals with natural immunity to disease, designed to treat various inflammatory and infectious conditions without the toxicity associated with traditional antibody treatments.

Brands and product families

  • True Human™ — Proprietary antibody discovery and development platform. Source

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on unnamed third-party contract research organizations to conduct clinical trials and manage regulatory processes. Source
  • Contract Manufacturing Organizations (CMOs) — The company utilizes unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business strengths to evaluate

  • Proprietary True Human™ antibody discovery platform Source

Business risks and research considerations

  • History of operating losses and lack of commercial revenue Source
  • Dependence on successful clinical trial outcomes and regulatory approvals Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

XBIT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.16
Market capitalization:
65.85M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -45.13M
Free cash flow:
USD -40.21M
Cash:
USD 109.53M
Total debt:
USD 0.00
EPS:
USD -1.48

What stands out

  • Free cash flow is USD -40.21M, negative for the stored period.
  • The balance sheet shows USD 109.53M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 109.53M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for XBIT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can XBIT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is XBIT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for XBIT to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of XBIT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research XBIT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.